Show simple item record

dc.contributor.authorGleeson, M
dc.contributor.authorHawkes, EA
dc.contributor.authorPeckitt, C
dc.contributor.authorWotherspoon, A
dc.contributor.authorAttygalle, A
dc.contributor.authorSharma, B
dc.contributor.authorDu, Y
dc.contributor.authorEthell, M
dc.contributor.authorPotter, M
dc.contributor.authorDearden, C
dc.contributor.authorHorwich, A
dc.contributor.authorChau, I
dc.contributor.authorCunningham, D
dc.date.accessioned2017-03-24T13:55:00Z
dc.date.issued2017-08-01
dc.identifier.citationLeukemia & lymphoma, 2017, 58 (8), pp. 1805 - 1813
dc.identifier.issn1042-8194
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/487
dc.identifier.eissn1029-2403
dc.identifier.doi10.1080/10428194.2016.1265114
dc.description.abstractSurvival for transformed follicular lymphoma (tFL) has improved in the rituximab era and the need for upfront stem cell transplantation (SCT) is unclear. We evaluated the outcomes for all patients treated with first-line chemotherapy for histologically-proven tFL at our institution from 2003-2013 (n = 87). The majority of patients (89.7%) did not receive a SCT as part of first-line management. With a median follow-up of 7.8 years the 5-year overall survival (OS) for all patients was 61.7%. Patients treated with R-CHOP without upfront SCT (n = 55/87) had a 5-year OS of 64.3%. In a Cox regression analysis of the entire cohort (n = 87) International Prognostic Index (IPI) risk group and presence of B symptoms at transformation were independently associated with OS in multivariate analysis (MVA). Our analysis confirms the improved survival of tFL in the rituximab era even in the absence of upfront SCT consolidation.
dc.formatPrint-Electronic
dc.format.extent1805 - 1813
dc.languageeng
dc.language.isoeng
dc.publisherTAYLOR & FRANCIS LTD
dc.subjectHumans
dc.subjectLymphoma, Follicular
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectNeoplasm Staging
dc.subjectTreatment Outcome
dc.subjectCombined Modality Therapy
dc.subjectRemission Induction
dc.subjectHematopoietic Stem Cell Transplantation
dc.subjectSurvival Analysis
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectLymphoma, Large B-Cell, Diffuse
dc.subjectNeoplasm Grading
dc.subjectMaintenance Chemotherapy
dc.subjectRituximab
dc.subjectAntineoplastic Agents, Immunological
dc.titleOutcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.
dc.typeJournal Article
rioxxterms.versionofrecord10.1080/10428194.2016.1265114
rioxxterms.licenseref.startdate2017-08
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfLeukemia & lymphoma
pubs.issue8
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume58
pubs.embargo.termsNot known
icr.researchteamMedicine (RMH Smith Cunningham)
dc.contributor.icrauthorSharma, Bhupinder


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record